-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
RSV investigational vaccines
Paused developmental vaccine candidates
Therapeutic area | Infectious disease | Status | Technology |
---|---|---|---|
Respiratory diseases | Respiratory syncytial virus (RSV) | Phase 3† Infants via maternal immunization* | |
Respiratory diseases | Respiratory syncytial virus (RSV) | Phase 1 Children between 2−6 years old | |
Respiratory diseases | Respiratory syncytial virus (RSV) | Phase 1 Adults 60+ years old* | Matrix-M™ adjuvant |
Therapeutic area
Respiratory diseases
Infectious disease
Respiratory syncytial virus (RSV)
Status
Phase 3†
Infants via maternal immunization*
Technology
Status
Phase 1
Children between 2−6 years old
Technology
Status
Phase 1
Adults 60+ years old*
Technology
Matrix-M™ adjuvant
About the candidates
RSV fusion (RSV F) recombinant protein nanoparticle investigational vaccines with or without aluminum phosphate or Matrix-M™ as an adjuvant.
Why it matters
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection and hospitalization in infants, young children, and older adults worldwide, causing over 3.2 million hospitalizations in children and 336,000 hospitalizations in adults ≥65 years of age.1,2 The development of RSV vaccines has been identified as a priority for WHO's Vaccine Product and Delivery Research Unit.3
†This trial did not meet its primary endpoint.
- Verwey C, Nunes M. Lancet Glob Health. 2020;8:1247–1248.
- Shi T, et al. J Infect Dis.. 2020;222:577–583.
- Respiratory Syncytial Virus (RSV). WHO. Available at: https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/respiratory-syncytial-virus-(rsv) [Accessed 3 Sept 2021].